CORONARY INTERVENTIONS

The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study

EuroIntervention 2017;12:1614-1622 published online ahead of print December 2015. DOI: 10.4244/EIJY15M12_02

Olivier Varenne1,2*, MD, PhD; Thomas Cuisset3, MD, PhD; Aurès Chaïb1,2, MD; Marie-Claude Morice4, MD; Manel Sabaté5, MD; Tian-Hai Koh6, MD; Isabelle Durand-Zaleski7, MD, PhD; Olivier Hanon2,8, MD, PhD; Kris Bogaerts9,10, PhD; Peter Sinnaeve11, MD, PhD

1. AP-HP, Hôpital Cochin, Service de Cardiologie, Paris, France; 2. Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France; 3. AP-HM, Hôpital de la Timone, Service de Cardiologie, Marseille, France; 4. Générale de Santé, Institut Cardio

Aims: In the elderly population, bare metal stents (BMS) are often preferred over drug-eluting stents (DES) because of the longer duration of dual antiplatelet therapy (DAPT) associated w

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bare metal stentcoronary artery diseaseclinical research

Coronary interventionsStents and scaffoldsAdjunctive pharmacotherapy

Share on Facebook Share on Twitter Share on Linkedin